These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37509231)

  • 21. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer.
    Lang C; Lantos A; Megyesfalvi Z; Egger F; Hoda MA; Mosleh B; Klikovits T; Oberndorfer F; Timelthaler G; Ferencz B; Fillinger J; Schwendenwein A; Querner AS; Boettiger K; Renyi-Vamos F; Hoetzenecker K; Laszlo V; Schelch K; Dome B
    ESMO Open; 2022 Dec; 7(6):100631. PubMed ID: 36399951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of Epithelial-Mesenchymal Transition Genes in Small Cell Lung Cancer Phenotypic Plasticity.
    Groves SM; Panchy N; Tyson DR; Harris LA; Quaranta V; Hong T
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors.
    Sato Y; Okamoto I; Kameyama H; Kudoh S; Saito H; Sanada M; Kudo N; Wakimoto J; Fujino K; Ikematsu Y; Tanaka K; Nishikawa A; Sakaguchi R; Ito T
    Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33202998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment.
    Hwang S; Hong TH; Park S; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Choi YL; Lee SH
    Transl Lung Cancer Res; 2021 Nov; 10(11):4209-4220. PubMed ID: 35004251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy.
    Chen HZ; Bonneville R; Paruchuri A; Reeser JW; Wing MR; Samorodnitsky E; Krook MA; Smith AM; Dao T; Miya J; Wang W; Yu L; Freud AG; Allenby P; Cole S; Otterson G; Shields P; Carbone DP; Roychowdhury S
    JTO Clin Res Rep; 2021 Apr; 2(4):100164. PubMed ID: 34590014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
    Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR; Curran WJ; Ivanov AA; Fu H; Lonial S; Ramalingam SS; Sun SY; Waller EK; Sica GL
    J Thorac Oncol; 2021 Mar; 16(3):464-476. PubMed ID: 33248321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment.
    Lo YC; Rivera-Concepcion J; Vasmatzis G; Aubry MC; Leventakos K
    JTO Clin Res Rep; 2023 Sep; 4(9):100561. PubMed ID: 37731627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer.
    Keogh A; Finn S; Radonic T
    Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.
    Yu N; Hwang M; Lee Y; Song BR; Kang EH; Sim H; Ahn BC; Hwang KH; Kim J; Hong S; Kim S; Park C; Han JY
    J Exp Clin Cancer Res; 2023 Jan; 42(1):37. PubMed ID: 36717865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autophagy-related gene expression classification defines three molecular subtypes with distinct clinical and microenvironment cell infiltration characteristics in colon cancer.
    Zhu S; Wu Q; Zhang B; Wei H; Li B; Shi W; Fang M; Zhu S; Wang L; Lang Zhou Y; Dong Y
    Int Immunopharmacol; 2020 Oct; 87():106757. PubMed ID: 32769067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
    Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
    J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer.
    Pozo K; Kollipara RK; Kelenis DP; Rodarte KE; Ullrich MS; Zhang X; Minna JD; Johnson JE
    iScience; 2021 Sep; 24(9):102953. PubMed ID: 34466783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional Profiling Reveals Mesenchymal Subtypes of Small Cell Lung Cancer with Activation of the Epithelial-to-Mesenchymal Transition and Worse Clinical Outcomes.
    Cho HJ; Hong SA; Ryu D; Hong SH; Kim TM
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
    Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
    Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report.
    Ito F; Sato T; Emoto K; Kaizuka N; Yagi K; Watanabe R; Hashiguchi MH; Ninomiya H; Ikematsu Y; Tanaka K; Domoto H; Shiomi T
    Mol Clin Oncol; 2021 Dec; 15(6):261. PubMed ID: 34790350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small cell lung cancer: Subtypes and therapeutic implications.
    Wang WZ; Shulman A; Amann JM; Carbone DP; Tsichlis PN
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):543-554. PubMed ID: 35398266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
    Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
    Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.